Nelly Mauras, MD

Dr. Nelly Mauras is Director of Research for Nemours Children’s Health in North Florida. She is Professor of Pediatrics at the Mayo Clinic College of Medicine, affiliated with Nemours. Dr. Mauras was the former Chief, Division of Endocrinology & Diabetes at Nemours Jacksonville. Dr. Mauras is an internationally recognized clinical research scientist focused on the interactions of hormones and nutrients in children and adolescents, particularly in type 1 diabetes, disorders of growth, estrogen action and Turner Syndrome. She has published over 230 peer reviewed papers to-date and lectured extensively nationally and internationally. Dr. Mauras has had a career track of successful external funding from multiple sources, including National Institutes of Health (NIH), private foundations, industry, and philanthropy. Dr. Mauras has been principal investigator for the Diabetes Research in Children Network, an NIH-funded consortium through multiple funding cycles investigating most recently the effect of type 1 diabetes on the brain in children. She has received a new 5-year NIH award on this topic funded by NIDDK. She was co-investigator in the NIH-funded Bionic Pancreas Research Group studying advanced diabetes technologies in children and has a significant interest in health care disparities in access to those technologies. She has also been keenly interested in the use of aromatase inhibitors to promote growth and in the impact of the route of estrogen delivery on estrogen action in hypogonadal girls. Dr. Mauras has been a key contributor for the growth and puberty sections of the international coalition for the Consensus Guidelines for the care of patients with Turner Syndrome. She has been an active participant of advisory panels, NIH study sections, and program committees. She is the director of the Clinical Research Center at Wolfson Children’s Hospital with which Nemours is affiliated. Dr. Mauras also remains an active clinician and teacher of pediatric house staff and pediatric and adult endocrine fellows.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:NovoNordiskTopic:Investigator initiated research study on GH impact on skeletal muscleDate added:10/07/2023Date updated:04/09/2026
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:NovoNordiskTopic:Use of Somapacitan in patients born SGA, Idiopathic short stature, Turner Syndrome, Noonan SyndromeDate added:10/07/2023Date updated:04/09/2026
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:DexcomTopic:Investigator initiated study on Disparities on use of advanced diabetes technologies in childrenDate added:10/07/2023Date updated:04/09/2026
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:PfizerTopic:Use of long-acting GH in children with GH deficiencyDate added:10/07/2023Date updated:04/09/2026
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:AgiosTopic:Nemours approved consultancy Re: aromatase blockage, an expected side effect in children with a rare hemolytic anemiaDate added:10/07/2023Date updated:04/09/2026

Facebook
X
LinkedIn
Forward